Dynacure has raised €47 million ($55 million) to take an antisense oligonucleotide therapy into the clinic. The French biotech picked up the centronuclear myopathy (CNM) prospect from its cofounder, Ionis Pharmaceuticals.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,